Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer

Video

In Partnership With:

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of genetic testing in pancreatic cancer.

Genetic testing has been a welcome addition to the pancreatic cancer armamentarium, says Pant.

Germline genetic testing can identify key inherited mutations within a patient’s blood, explains Pant. Conversely, somatic genetic testing identifies aberrations within the tumor.

Germline and somatic testing results can inform whether a patient is a candidate for targeted therapy, Pant says.

Currently, the National Comprehensive Cancer Network and the ASCO guidelines recommend that all patients with pancreatic cancer undergo germline testing to identify BRCA1/2 mutations, concludes Pant.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles